Table 1.
Baseline patient and disease characteristics
| Characteristica | Non-Hodgkin’s lymphoma subtype cohort |
||||
|---|---|---|---|---|---|
| DLBCL | FL | Other iNHL | MCL | Total | |
| N = 35 | N = 34 | N = 11b | N = 12 | N = 92 | |
| Age, years | |||||
| Median | 71 | 62 | 73 | 64.5 | 66.5 |
| Range | 35–90 | 40–87 | 45–83 | 56–74 | 35–90 |
| Sex | |||||
| Male | 24 (69) | 16 (47) | 5 (45) | 11 (92) | 56 (61) |
| Female | 11 (31) | 18 (53) | 6 (55) | 1 (8) | 36 (39) |
| ECOG PS | |||||
| 0 | 19 (54) | 22 (65) | 9 (82) | 6 (50) | 56 (61) |
| 1 | 15 (43) | 10 (29) | 2 (18) | 5 (42) | 32 (35) |
| 2 | 1 (3) | 2 (6) | 0 | 1 (8) | 4 (4) |
| Ethnicity | |||||
| White | 33 (94) | 32 (94) | 11 (100) | 11 (92) | 87 (95) |
| Other | 2 (6) | 2 (6) | 0 | 1 (8) | 5 (5) |
| Ann Arbor stage | |||||
| Stages I–II | 4 (11) | 5 (15) | 0 | 1 (8) | 10 (11) |
| Stages III–IV | 30 (86) | 29 (85) | 11 (100) | 11 (92) | 81 (88) |
| Unknown | 1 (3) | 0 | 0 | 0 | 1 (1) |
| International prognostic indexc | |||||
| High risk | 19 (54) | 10 (29) | – | 9 (75) | – |
| Low risk | 15 (43) | 23 (68) | – | 3 (25) | – |
| Missing | 1 (3) | 1 (3) | – | 0 | – |
| Prior lines of therapy | |||||
| 1 | 12 (34) | 13 (38) | 3 (27) | 3 (25) | 31 (34) |
| 2 | 8 (23) | 4 (12) | 2 (18) | 1 (8) | 15 (16) |
| 3 | 9 (26) | 5 (15) | 2 (18) | 2 (17) | 18 (20) |
| >3 | 6 (17) | 12 (35) | 4 (36) | 6 (50) | 28 (30) |
| DoR to most recent treatment | |||||
| ≤12 months | 26 (74) | 17 (50) | 8 (73) | 7 (58) | 58 (63) |
| >12 months | 3 (9) | 15 (44) | 3 (27) | 4 (33) | 25 (27) |
| Unknown | 6 (17) | 2 (6) | 0 | 1 (8) | 9 (10) |
| Time since last therapy | |||||
| ≤3 months | 16 (46) | 6 (18) | 3 (27) | 5 (42) | 30 (33) |
| >3 months | 19 (54) | 28 (82) | 8 (73) | 7 (58) | 62 (67) |
| Rituximab refractoryd | |||||
| Yes | 24 (69) | 17 (50) | 5 (45) | 6 (50) | 52 (57) |
| No | 11 (31) | 17 (50) | 6 (55) | 6 (50) | 40 (43) |
| Off rituximab >6 months | |||||
| Yes | 21 (60) | 29 (85) | 10 (91) | 11 (92) | 71 (77) |
| No | 14 (40) | 5 (15) | 1 (9) | 1 (8) | 21 (23) |
| Prior autologous stem cell transplant | 4 (11) | 6 (18) | 2 (18) | 1 (8) | 13 (14) |
| FCGR2A codon 131 statuse | |||||
| HH | 11 (31) | 9 (26) | 1 (9) | 3 (25) | 24 (26) |
| HR | 9 (26) | 13 (38) | 4 (36) | 6 (50) | 32 (35) |
| RR | 12 (34) | 3 (9) | 2 (18) | 1 (8) | 18 (20) |
| Missing | 3 (9) | 9 (26) | 4 (36) | 2 (17) | 18 (20) |
| FCGR3A codon 158 statusf | |||||
| VV | 5 (14) | 4 (12) | 0 | 1 (8) | 10 (11) |
| FV | 10 (29) | 12 (35) | 2 (18) | 6 (50) | 30 (33) |
| FF | 17 (49) | 9 (26) | 5 (45) | 3 (25) | 34 (37) |
| Missing | 3 (9) | 9 (26) | 4 (36) | 2 (17) | 18 (20) |
Data are number of patients (%) unless otherwise stated.
As determined at screening or at baseline.
Including nine patients with marginal zone lymphoma and two with chronic lymphocytic leukemia.
Assessed according to lymphoma subtype-specific scoring systems: DLBCL, International Prognostic Index; FL, Follicular Lymphoma International Prognostic Index; MCL, Mantle Cell Lymphoma International Prognostic Index.
Patients were considered rituximab refractory if they had no response or a response lasting <6 months to a prior rituximab-containing therapy.
Due to a single nucleotide polymorphism, codon 131 of the autosomal FCGR2A gene codes for either histidine (H) or arginine (R).
Due to a single nucleotide polymorphism, codon 158 of the autosomal FCGR3A gene codes for either valine (V) or phenylalanine (F).
DLBCL, diffuse large B-cell lymphoma; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; iNHL indolent non-Hodgkin’s lymphoma; MCL, mantle cell lymphoma.